Science Corporation Raises $400 Million at $3.5 Billion Valuation for Brain Tech
Updated
Updated · TechCrunch · Nov 17
Science Corporation Raises $400 Million at $3.5 Billion Valuation for Brain Tech
1 articles · Updated · TechCrunch · Nov 17
Summary
$400 million in Series D funding gives Science Corporation fresh capital to expand its neurotechnology work, with investors valuing the startup at $3.5 billion.
PRIMA — the company's first product, a wearable and implantable vision chip — is already approved in Europe and available in Germany, and is now being trialed for Stargardt's disease.
The new funding is aimed in part at bringing PRIMA to the U.S. through the FDA's Humanitarian Device Exemption after the agency accepted that advanced macular degeneration in both eyes is rare enough for that pathway.
Science, founded in 2021 by former Neuralink president Max Hodak, is also designing initial human trials of a bio-hybrid brain interface with Yale's Murat Günel, targeting conditions including Parkinson's disease.
Could a former Neuralink executive's new $3.5 billion startup ultimately beat his old company's brain chip to the mass market?
Will fusing living neurons with silicon revolutionize brain implants, or create unprecedented ethical nightmares for medical regulators?
Can a retinal chip meant for rare blindness utilize FDA exemptions to eventually treat millions with age-related vision loss?
$400 Million Raised: How Science Corp’s PRIMA Retinal Implant Is Shaping the BCI Industry and Vision Restoration
Overview
Science Corporation’s breakthrough clinical trial for the PRIMA retinal implant, published in the New England Journal of Medicine, showed significant vision improvement for patients. This success sparked strong investor confidence, leading to a $400 million Series D funding round and raising the company’s valuation to $3.5 billion. Science Corp then expanded its manufacturing by acquiring MEMSCAP’s U.S. foundry and launching Science Foundry, which helps offset production costs. After acquiring Pixium Vision and integrating its technology, Science Corp secured European regulatory approval and began commercial rollout in Germany. Looking ahead, the company is developing a next-generation PRIMA chip to reach millions of patients worldwide.